AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11280651 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive dilatational tracheostomy (PDT)
Number of subjects: 127
Study 11280651 — intervention group
Group type: COMPARATOR
Intervention: Forceps dilatational tracheostomy (FDT)
Number of subjects: 127
Study 9158083 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion at 2 mg/h (group 1, n = 7)
Number of subjects: 20
Study 9158083 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg i.v. bolus (group 2, n = 7)
Number of subjects: 20
Study 9158083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both naloxone and metoclopramide (group 3, n = 6)
Number of subjects: 20
Study 9158083 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 8387963 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin (400 mg loading dose on day 1, followed by 200 mg s.i.d.)
Number of subjects: 163
Study 8387963 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (300 mg b.i.d.)
Number of subjects: 163
Study 3549044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 21
Study 31182400 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antimicrobial prophylaxis
Number of subjects: 600
Study 31182400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 28902371 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinless navigation
Number of subjects: 100
Study 28902371 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 100
Study 27391321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated prevention programme (NCPP) consisting of four outpatient nurse clinic visits in the first 6 months after the index event, focusing on healthy lifestyles, biometric risk factors, and medication adherence, in addition to usual care.
Number of subjects: 754
Study 27391321 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control group).
Number of subjects: 754
Study 24819305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) continued for 2 years
Number of subjects: 0
Study 24819305 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT) discontinued for 2 years
Number of subjects: 0
Study 23114452 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care project 'Gesundes Kinzigtal'
Number of subjects: 1205
Study 23114452 — intervention group
Group type: COMPARATOR
Intervention: Control groups (two control groups)
Number of subjects: 1205
Study 20102912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4570
Study 20102912 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 4570
Study 18594002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Carboplatin
Number of subjects: 0
Study 18594002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine dose-based models
Number of subjects: 0
Study 18594002 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-based exposure metrics for gemcitabine and its metabolites
Number of subjects: 0
Study 15670986 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine 990 mg/day + 4 mL/day linseed oil (weeks 5-8)
Number of subjects: 20
Study 15670986 — intervention group
Group type: COMPARATOR
Intervention: 4 mL/day linseed oil + 990 mg/day l-carnitine (weeks 5-8)
Number of subjects: 20
Study 15670986 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine 990 mg/day (weeks 1-4)
Number of subjects: 20
Study 15670986 — intervention group
Group type: COMPARATOR
Intervention: 4 mL/day linseed oil (weeks 1-4)
Number of subjects: 20
Study 12145060 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg)
Number of subjects: 0
Study 10022399 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa plus GH (0.3 mg/kg x week s.c., 6 days weekly, for 2‐4 years)
Number of subjects: 20
Study 10022399 — intervention group
Group type: COMPARATOR
Intervention: GnRHa alone
Number of subjects: 20
Study 8574277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment (5.0 MJ/day diet) for 16 weeks
Number of subjects: 0
Study 8574277 — intervention group
Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 0
Study 2383532 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya-bean fat diet
Number of subjects: 25
Study 2383532 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut fat diet
Number of subjects: 25
Study 7417123 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate heat load (30 degrees C ET)
Number of subjects: 9
Study 7417123 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe heat load (35 degrees C ET)
Number of subjects: 9
Study 7417123 — intervention group
Group type: COMPARATOR
Intervention: Comfort (21 degrees C ET)
Number of subjects: 9
Study 31103125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates Group (PG)
Number of subjects: 24
Study 31103125 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 24
Study 28349528 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing-2-gether (P2G) intervention
Number of subjects: 175
Study 26342560 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa 600 mg/day for 8 weeks
Number of subjects: 219
Study 26342560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 23157710 — intervention group
Group type: EXPERIMENTAL
Intervention: cCABG (conventional coronary artery bypass grafting with cardiopulmonary bypass and cardioplegic arrest‐induced I/R)
Number of subjects: 46
Study 23157710 — intervention group
Group type: EXPERIMENTAL
Intervention: cCABG
Number of subjects: 46
Study 23157710 — intervention group
Group type: COMPARATOR
Intervention: OPCAB (off-pump coronary artery bypass grafting)
Number of subjects: 46
Study 21372737 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (30 minutes of music)
Number of subjects: 54
Study 21372737 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (quiet rest)
Number of subjects: 54
Study 21372737 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 54
Study 21372737 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 54
Study 21372737 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention and Usual-care group
Number of subjects: 54
Study 19750309 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air blanket warmed at 38 degrees C for 30 minutes before anesthetic induction and up to 120 minutes after anesthetic induction (Gtotal)
Number of subjects: 60
Study 19750309 — intervention group
Group type: COMPARATOR
Intervention: Forced-air blanket warmed at 38 degrees C for 30 minutes before anesthetic induction (Gpre)
Number of subjects: 60
Study 19750309 — intervention group
Group type: COMPARATOR
Intervention: Forced-air blanket warmed at 38 degrees C after anesthetic induction up to 120 minutes (Gintra)
Number of subjects: 60
Study 19750309 — intervention group
Group type: COMPARATOR
Intervention: Control group (Gcont) with no warming
Number of subjects: 60
Study 16962066 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50 mg
Number of subjects: 238
Study 16962066 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 500 mg
Number of subjects: 238
Study 16962066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 15462688 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily
Number of subjects: 831
Study 11704448 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 40
Study 11704448 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 40
Study 11704448 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg
Number of subjects: 40
Study 11704448 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg + Atropine 0.01 mg/kg
Number of subjects: 40
Study 9042843 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829
Study 9042843 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1829
Study 9042843 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PTCA and CABG
Number of subjects: 1829
Study 9042843 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829
Study 9042843 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1829
Study 7513403 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 12
Study 7513403 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 12
Study 2963525 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol (400 mg once daily)
Number of subjects: 9
Study 2963525 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 30165909 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical chest compression device (LUCAS 2/3, Jolife AB/Stryker, Lund, Sweden)
Number of subjects: 330
Study 30165909 — intervention group
Group type: COMPARATOR
Intervention: Manual chest compressions
Number of subjects: 330
Study 26803374 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki (GI)
Number of subjects: 256
Study 26803374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (GP)
Number of subjects: 256
Study 24991908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (24 weekly group sessions led by community care workers)
Number of subjects: 390
Study 24991908 — intervention group
Group type: COMPARATOR
Intervention: Standard care (S)
Number of subjects: 390
Study 21835497 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered online model
Number of subjects: 0
Study 21835497 — intervention group
Group type: COMPARATOR
Intervention: In-office visits
Number of subjects: 0
Study 19269924 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT)
Number of subjects: 32
Study 19269924 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT) - 100 hours
Number of subjects: 32
Study 19269924 — intervention group
Group type: COMPARATOR
Intervention: Computer games (CGs) control condition
Number of subjects: 32
Study 18564693 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg twice daily for 7 days
Number of subjects: 50
Study 18564693 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study 15194207 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention with a consistent support person
Number of subjects: 127
Study 15194207 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 127
Study 11739071 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (AAT) conducted in weekly 4-hour sessions
Number of subjects: 10
Study 11739071 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched patients)
Number of subjects: 10
Study 9631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg
Number of subjects: 349
Study 9631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 300 mg
Number of subjects: 349
Study 9631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 450 mg
Number of subjects: 349
Study 9631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (all dosages)
Number of subjects: 349
Study 9631993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 8052779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mitomycin C plus tegafur
Number of subjects: 136
Study 8052779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mitomycin C plus UFT
Number of subjects: 136
Study 8052779 — intervention group
Group type: COMPARATOR
Intervention: High-dose mitomycin C
Number of subjects: 136
Study 3342553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g before surgery, 500 mg every 8 hours for 6 doses)
Number of subjects: 97
Study 3342553 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (2 g before surgery, 1 g every 8 hours for 6 doses)
Number of subjects: 97
Study 3342553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 97
Study 3342553 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 97
Study 31941372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cholesterol efflux capacity
Number of subjects: 167
Study 31941372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sphingosine-1-phosphate levels
Number of subjects: 167
Study 31941372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low apolipoprotein A-I levels
Number of subjects: 167
Study 31941372 — intervention group
Group type: EXPERIMENTAL
Intervention: High HDL oxidative inflammatory index values
Number of subjects: 167
Study 31941372 — intervention group
Group type: EXPERIMENTAL
Intervention: High HDL oxidative-inflammation index values
Number of subjects: 167
Study 28083879 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month care coordination intervention delivered through community-based nonclinical care coordinators, supported by an interdisciplinary clinical team
Number of subjects: 303
Study 28083879 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 303
Study 26685937 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimen-driven margin assessment
Number of subjects: 71
Study 26685937 — intervention group
Group type: COMPARATOR
Intervention: Patient-driven margin assessment
Number of subjects: 71
Study 25630840 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counselling plus Traditional Chinese Medicine (TCM) acupuncture
Number of subjects: 35
Study 25630840 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counselling plus sham acupuncture
Number of subjects: 35
Study 23043203 — intervention group
Group type: EXPERIMENTAL
Intervention: Free daily school breakfast programme (SBP)
Number of subjects: 424
Study 23043203 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no SBP)
Number of subjects: 424
Study 20391093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten 30‐s passive knee flexor muscle stretches
Number of subjects: 20
Study 20391093 — intervention group
Group type: COMPARATOR
Intervention: No stretching (control condition)
Number of subjects: 20
Study 18581174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear shape factor analysis
Number of subjects: 98
Study 18581174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement
Number of subjects: 98
Study 18581174 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement
Number of subjects: 98
Study 16527709 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 148
Study 16527709 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomic myomectomy
Number of subjects: 148
Study 14639446 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI; 70-80% heart rate reserve)
Number of subjects: 6
Study 14639446 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity (LI; 40-50% heart rate reserve)
Number of subjects: 6
Study 14639446 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between VO(2Peak) and insulin sensitivity
Number of subjects: 6
Study 10634221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 0
Study 10634221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9052319 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer learning (RELAX software)
Number of subjects: 23
Study 9052319 — intervention group
Group type: COMPARATOR
Intervention: Textbook learning
Number of subjects: 23
Study 8245278 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological remediation tasks (n = 15)
Number of subjects: 60
Study 8245278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecologically relevant tasks (n = 15)
Number of subjects: 60
Study 8245278 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo tasks (n = 16)
Number of subjects: 60
Study 8245278 — intervention group
Group type: COMPARATOR
Intervention: No intervention (n = 15)
Number of subjects: 60
Study 3895539 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-specific transfusions (DST) combined with conventional immunosuppressive therapy (azathioprine, prednisone, and antilymphoblast globulin)
Number of subjects: 49
Study 3895539 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine and prednisone without DST
Number of subjects: 49
Study 3895539 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine without prior DST
Number of subjects: 49
Study 30739167 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 30
Study 29310631 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g CTE in 400 mL of water
Number of subjects: 15
Study 29310631 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g CTE in 400 mL of water
Number of subjects: 15
Study 29310631 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g CTE with 50 g sucrose in 400 mL of water
Number of subjects: 15
Study 29310631 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g CTE with 50 g sucrose in 400 mL of water
Number of subjects: 15
Study 29310631 — intervention group
Group type: COMPARATOR
Intervention: 50 g sucrose in 400 mL water
Number of subjects: 15
Study 26540622 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cervical cancer screening guidelines
Number of subjects: 1268
Study 24385331 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge nurse-led telephone support
Number of subjects: 135
Study 24385331 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital discharge care (Control)
Number of subjects: 135
Study 22486584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mountain hiking (9-week hiking phase)
Number of subjects: 20
Study 22486584 — intervention group
Group type: COMPARATOR
Intervention: Control phase (9-week control phase)
Number of subjects: 20
Study 22486584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mountain hiking (within the hiking phase)
Number of subjects: 20
Study 20412139 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupine flour (DBPCFC)
Number of subjects: 372
Study 20412139 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupine flour (dietary record)
Number of subjects: 372
Study 20412139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to lupine flour
Number of subjects: 372
Study 20412139 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE measurement
Number of subjects: 372
Study 17698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low total testosterone (<300 ng/dl)
Number of subjects: 1475
Study 17698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low free testosterone (<5 ng/dl)
Number of subjects: 1475
Study 17698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of androgen deficiency
Number of subjects: 1475
Study 17698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic androgen deficiency
Number of subjects: 1475
Study 17698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related prevalence of symptomatic androgen deficiency
Number of subjects: 1475
Study 12771037 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA), 4 g daily for 3 months
Number of subjects: 42
Study 12771037 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (OA), 4 g daily for 3 months
Number of subjects: 42
Study 11145387 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (Lubinus IP)
Number of subjects: 100
Study 11145387 — intervention group
Group type: COMPARATOR
Intervention: Osteosynthesis with two parallel and percutaneously inserted screws (Olmed)
Number of subjects: 100
Study 9768319 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 detection task
Number of subjects: 20
Study 9768319 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-induced transient disruption of respiratory pattern
Number of subjects: 20
Study 9768319 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 detection threshold
Number of subjects: 20
Study 8463443 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (maximum dose of 300 mg per day)
Number of subjects: 36
Study 8463443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 4087830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampicin (600 mg)
Number of subjects: 12
Study 4087830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rifampicin (600 mg)
Number of subjects: 12
Study 4087830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous rifampicin therapy
Number of subjects: 12
Study 30917064 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to left prefrontal cortex
Number of subjects: 0
Study 30917064 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to left primary motor cortex (M1)
Number of subjects: 0
Study 30917064 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to right prefrontal cortex
Number of subjects: 0
Study 30917064 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 0
Study 27885522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 40
Study 27885522 — intervention group
Group type: COMPARATOR
Intervention: Fractional Er:YAG laser
Number of subjects: 40
Study 26514478 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education based on the Health Belief Model
Number of subjects: 120
Study 26514478 — intervention group
Group type: COMPARATOR
Intervention: Multimedia education based on the Health Belief Model
Number of subjects: 120
Study 26514478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both educational methods
Number of subjects: 120
Study 23320436 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg gemigliptin qd
Number of subjects: 425
Study 23320436 — intervention group
Group type: COMPARATOR
Intervention: 100 mg sitagliptin qd
Number of subjects: 425
Study 23320436 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg gemigliptin bid
Number of subjects: 425
Study 23320436 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin treatment
Number of subjects: 425